Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
CRANBURY, N.J., Feb. 18, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, will host a conference call and live audio webcast on Friday, February 26, 2016 at 8:30 a.m. ET to discuss financial results for the year ended December 31, 2015.
The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call at 8:00 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international) participant code 52850523.
A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register and to download and install any necessary software.
A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on February 26, 2016. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 52850523.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders.
FOLD-G
CONTACT: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044
